{"id":630,"date":"2026-06-30T18:08:33","date_gmt":"2026-06-30T16:08:33","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/new-findings-from-asco-2026\/"},"modified":"2026-07-20T16:50:35","modified_gmt":"2026-07-20T14:50:35","slug":"new-findings-from-asco-2026","status":"publish","type":"post","link":"https:\/\/studienportal-endometriumkrebs.de\/en\/new-findings-from-asco-2026\/","title":{"rendered":"New Findings from ASCO 2026"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"630\" class=\"elementor elementor-630 elementor-622\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9892029 e-flex e-con-boxed e-con e-parent\" data-id=\"9892029\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7306ff9 elementor-widget elementor-widget-text-editor\" data-id=\"7306ff9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>As part of the NOGGO Gynecological Oncology Update, the most important studies from this year&#8217;s ASCO Congress were presented. <\/p><h2 data-section-id=\"1l4xar7\" data-start=\"3693\" data-end=\"3758\">RUBY Study: Long-term Benefit of Immunotherapy Confirmed<\/h2><p data-start=\"3760\" data-end=\"4002\">New long-term data from the <strong data-start=\"3783\" data-end=\"3798\">RUBY study<\/strong> confirm the sustained benefit of the immunotherapy <strong data-start=\"3851\" data-end=\"3866\">dostarlimab<\/strong> in combination with chemotherapy for patients with <strong data-start=\"3927\" data-end=\"3955\">dMMR endometrial cancer<\/strong> (tumors with a DNA repair deficiency).<\/p><p data-start=\"4004\" data-end=\"4351\">Long-term observation shows that many patients benefit permanently from the treatment and live long-term without disease progression. According to the study authors, there is even the prospect of <strong data-start=\"4281\" data-end=\"4350\">permanent disease control or even a potential cure<\/strong> for a portion of these patients.<\/p><p data-start=\"4353\" data-end=\"4507\">The results thus underscore the high significance of the combination of dostarlimab and chemotherapy for patients with dMMR endometrial cancer.<\/p><p data-start=\"4353\" data-end=\"4507\"> <\/p><p data-start=\"4353\" data-end=\"4507\">Abstracts of the presented studies can be found directly on the <a href=\"https:\/\/www.asco.org\/annual-meeting\/search?filters=%7B%22mediaTypes%22:%5B%22Abstracts%22%5D%7D&#038;userInput=&#038;sortBy=AbstractBrowse&#038;contentKey=ANNUAL_MEETING&#038;contentKeyYear=2026\" target=\"_blank\" rel=\"noopener\">ASCO<\/a> website (the site is in English).<\/p><p data-start=\"4353\" data-end=\"4507\">In the coming days, you will also find short videos on the highlights of ASCO on our social media channels!<\/p><p> <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>As part of the NOGGO Gynecological Oncology Update, the most important studies from this year&#8217;s ASCO Congress were presented. RUBY Study: Long-term Benefit of Immunotherapy Confirmed New long-term data from the RUBY study confirm the sustained benefit of the immunotherapy dostarlimab in combination with chemotherapy for patients with dMMR endometrial cancer (tumors with a DNA [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":631,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1,22],"tags":[],"class_list":["post-630","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nicht-kategorisiert","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/posts\/630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=630"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/posts\/630\/revisions"}],"predecessor-version":[{"id":632,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/posts\/630\/revisions\/632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/media\/631"}],"wp:attachment":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/categories?post=630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/tags?post=630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}